Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 45,984

Document Document Title
WO/2014/048033
The present invention relates to polymorphic forms of the compound of Formula (I) (i.e., ethyl 2-cyano-3,12-dioxoIeana-1,9(1l)-dien-28-oate (CDDO ethyl ester)) and methods of using them for treating a variety of disease states such as ca...  
WO/2014/052933
This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridop...  
WO/2014/049471
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2014/049366
Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of s...  
WO/2014/047707
The present invention relates to a compound of formula (I) or to a pharmaceutically acceptable salt thereof with analgesic activity. In particular, the compounds according to the present invention are useful for treating or preventing ac...  
WO/2014/049133
The present invention relates to indole derivatives useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive a...  
WO/2014/052427
The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alph...  
WO/2014/052807
Methods for alleviating symptoms related to Multiple Sclerosis by administration of apoaequorin are provided by the present invention. Such symptoms include, for example, sleep quality, energy quality, mood quality, memory quality or pain.  
WO/2014/052398
The present invention relates to spirocyclic indane imidazole 4-amines and their use as inhibitors of the β-secretase enzyme (BACEl) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic...  
WO/2014/052669
Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1.  
WO/2014/051388
The present invention relates to a pharmaceutical composition comprising a sulfamide derivative having an adamantyl group as an active ingredient for preventing or treating brain diseases or ischemic heart diseases. The sulfamide derivat...  
WO/2014/048370
Methods and compounds for treating, inhibiting, and preventing traumatic brain injury are provided. Methods include administering 7,8-dihydroxyflavone and derivatives thereof.  
WO/2014/051567
Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first...  
WO/2014/048165
Disclosed is a compound as a potassium channel modulator, which is a compound of general formula (I) or a pharmaceutically acceptable salt thereof. Such compound can be used to prepare drugs for increasing the flow of ions in potassium c...  
WO/2014/052461
The invention features compositions for use in increasing neuron or neurite growth, including for the treatment of Central Nervous System (CNS) injury, such as human arylsulfatase B.  
WO/2014/052659
The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention ...  
WO/2014/048071
The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR an...  
WO/2014/046391
The present invention relates to a pharmaceutical composition for treating or preventing protein tyrosine phosphatase sigma (PTPσ)-mediated diseases, and provides a pharmaceutical composition for treating or preventing PTPσ-mediate dis...  
WO/2014/046544
The present invention relates to compounds compound according to Formula (1): and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have serotonin (5-HT) transporter inhibitory effects and 5-HT 2C receptor...  
WO/2014/046247
 Provided is a method for adjusting the balance of TNF-R1 and TNF-R2 in cells present at a target organ, tissue or site. In the adjustment method provided by the present invention, (1) if raising the abundance of TNF-R2 present in a ta...  
WO/2014/045156
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...  
WO/2014/045031
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing...  
WO/2014/044790
The present invention relates to a DYRK1A inhibitor or an inhibitor of DYRK1A gene expression for use in the treatment or prevention of hypothyroidism in a Down Syndrome patient.  
WO/2014/047116
Provided herein is technology relating to liposomes and particularly, but not exclusively, to compositions of liposomes encapsulating a biologically active agent, methods of preparing liposomes encapsulating a biologically active agent, ...  
WO/2014/045162
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of trea...  
WO/2014/047323
Embodiments of the invention generally relate to methods and supplements for treating post-traumatic stress disorder in human beings. Other embodiments of the invention generally relate to methods and supplements for improving sleep effi...  
WO/2014/044721
The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with cha...  
WO/2014/047153
The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition...  
WO/2014/046472
The present invention provides a rivastigmine medicine having improved stability. The invention also provides a method, for packing pharmaceutical medicines containing rivastigmine, capable of improving stability.  
WO/2014/041007
The present invention relates to compounds of formula (I) wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy...  
WO/2014/040969
The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein (N1) is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; (N2) is phenyl or pyridinyl...  
WO/2014/041106
The invention relates to compounds of formula (I), wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen; X1 is -N= or ...  
WO/2014/041111
Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.  
WO/2014/041179
A method of treating or preventing peripheral neuropathy in a subject determined to be in need thereof comprising: topically administering to the subject an anti-peripheral neuropathic compound acting as GFRα3 type receptor agonist.  
WO/2014/040228
The present invention relates to the stabilised amorphous form of the compound of formula (I), to a process for its preparation and also to pharmaceutical compositions or medicaments containing it.  
WO/2014/043110
The invention provides powerful methods and compositions for designing, selecting, fine-tuning and optimizing polymer nanogel and other supramolecular assemblies for various properties including, for example, particle size, density and m...  
WO/2014/043685
Disclosed are compositions, such as liquid and solid nutritional compositions, that contain beta-hydroxy-beta-methylbutyric acid and optionally at least one protein, carbohydrate, fat, or a combination of protein, carbohydrate, and fat. ...  
WO/2014/043330
Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods ...  
WO/2014/042238
The invention provides a novel sulfonamide compound useful as a drug having a TRPM8-blocking effect. Specifically, the invention provides a sulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I...  
WO/2014/042176
Provided are an industrially useful method for producing a fused-heterocyclic derivative or salt thereof which is useful as a preventive agent, therapeutic agent, reproductive adjustment agent, contraceptive, ovulation-inducing agent, or...  
WO/2014/041175
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q1, Q2 have the following meanings: X is C-R3 or...  
WO/2014/043368
Disclosed are methods for enhancing learning and/or memory, enhancing memory acquisition, memory retention and recall by inducing a higher long-term potentiation in hippocampal neuronal synapsis in individuals. The methods include admini...  
WO/2014/043068
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and...  
WO/2014/039501
Bolaamphiphilic compounds are provided according to formula (I): where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into anim...  
WO/2014/037532
The present invention describes methods of treating dementia comprising administering an effective daily dose of N-(2-(6-fluoro-lH-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropo xy)benzylamine to improve or augment the effect of an acetylcho...  
WO/2014/039074
The present invention generally relates to therapeutic compositions for the treatment of mammalian disease and related methods. It more specifically relates to compositions comprising peptides for the treatment of inflammation and method...  
WO/2014/036595
The present disclosure relates to quinoline compounds of formula I, compositions comprising them and methods and uses for the treatment of central nervous system disorders, such as mood disorders (eg. depression), anxiety disorders, and ...  
WO/2014/039411
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may ...  
WO/2014/037412
The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising a...  
WO/2014/039908
Provided are methods and compositions for inducing cells of the inner ear (for example, cochlear and utricular hair cells) to reenter to cell cycle and to proliferate. More particularly, the invention relates to the use of agents that in...  

Matches 351 - 400 out of 45,984